Immunome, Inc. (NASDAQ:IMNM) CTO Philip Tsai Purchases 21,000 Shares

Immunome, Inc. (NASDAQ:IMNM) CTO Philip Tsai bought 21,000 shares of the firm’s stock in a transaction dated Thursday, November 21st. The stock was purchased at an average price of $9.43 per share, with a total value of $198,030.00. Following the transaction, the chief technology officer now owns 21,000 shares in the company, valued at approximately $198,030. This represents a ∞ increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Immunome Stock Performance

Shares of NASDAQ:IMNM traded up $1.16 during trading hours on Monday, hitting $10.98. The stock had a trading volume of 351,854 shares, compared to its average volume of 771,478. The stock’s fifty day simple moving average is $12.58 and its 200 day simple moving average is $13.58. The firm has a market capitalization of $685.37 million, a price-to-earnings ratio of -1.35 and a beta of 1.82. Immunome, Inc. has a 1-year low of $6.93 and a 1-year high of $30.96.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on the stock. Wedbush reaffirmed an “outperform” rating and issued a $33.00 price objective on shares of Immunome in a report on Friday, October 25th. Piper Sandler decreased their price target on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating for the company in a report on Thursday, November 14th. Finally, Stephens began coverage on shares of Immunome in a research note on Friday, November 8th. They set an “overweight” rating and a $30.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $28.83.

Hedge Funds Weigh In On Immunome

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Quest Partners LLC bought a new stake in Immunome during the 2nd quarter valued at $81,000. Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Immunome during the second quarter valued at about $97,000. Arizona State Retirement System lifted its holdings in Immunome by 9.2% in the second quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock worth $131,000 after purchasing an additional 918 shares during the period. Intech Investment Management LLC bought a new position in Immunome in the 3rd quarter valued at about $219,000. Finally, AQR Capital Management LLC increased its stake in Immunome by 34.6% during the 2nd quarter. AQR Capital Management LLC now owns 16,064 shares of the company’s stock valued at $194,000 after buying an additional 4,129 shares during the period. 44.58% of the stock is owned by institutional investors.

About Immunome

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.